Form D · Biotechnology
U1 Bio, Inc.
San Francisco, CA · CIK 0001850995
Offering snapshot reported Jun 8, 2022 · SEC filing
- Reported sold
- $9.5M Offering amount: $10.7M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- May 31, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 8, 2022 | Initial | $9,498,000 | No comparison | 26 | SEC filing |
| Mar 15, 2021 | Initial | $450,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-448526
$650,000 of the Total Offering Amount results from the conversion of SAFEs, so the amount of new money in the Offering is $10,000,000
Source: Form D, filed Jun 8, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Konstantinos Charizanis | Director, Executive |
| David Nelles | Director, Executive |
| Sharam Seyedin Noor | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
18 Bartol Street #966
San Francisco, CA, 94133
San Francisco, CA, 94133